Cost‐Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate‐Severe Crohn's Disease in Biologic‐Naïve Patients

Study Objective Ustekinumab was recently approved by the United States U.S. Food and Drug Administration for the treatment of Crohn's disease. In this analysis, we aimed to compare the cost‐effectiveness of ustekinumab, infliximab, or adalimumab for the treatment of moderate‐severe Crohn's...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacotherapy 2019-02, Vol.39 (2), p.118-128
Hauptverfasser:	Aliyev, Elmar R., Hay, Joel W., Hwang, Caroline
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - economics Adalimumab - therapeutic use Adult Antagonists Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Biological products biologics Biosimilar Pharmaceuticals computer modeling Computer simulation Corticoids Corticosteroids Cost-Benefit Analysis Costs Crohn Disease - drug therapy Crohn Disease - pathology Crohn's disease C‐reactive protein Decision trees Drug development Female gastroenterology Humans Immunomodulation Immunomodulators Immunotherapy Infliximab Infliximab - economics Infliximab - therapeutic use Male Markov chains Medical treatment Models, Economic Monoclonal antibodies Patients pharmacoeconomics quality of life Quality-Adjusted Life Years Sensitivity analysis Severity of Illness Index TNF inhibitors Transition probabilities Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-α United States Ustekinumab - economics Ustekinumab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!